RXi Pharmaceuticals focuses on immuno-oncology, hemp firm switches CEO and why haemorrhoid cream maker is sitting pretty

Proactive's early take on the day's small-cap news ...
Body heal thyself - immuno-oncology uses the immune system to combat cancer

Clinical-stage drug developer RXi Pharmaceuticals Corp (NASDAQ:RXII) said it will focus on its “expanding and promising” immuno-oncology programs.

This, according to chief executive Dr Geert Cauwenbergh, “will accelerate growth and in turn support a return on investment for our shareholders”.

"The positive clinical results recently announced from our phase II dermatology study validate the safety and efficacy of our sd-rxRNA therapeutics in humans. These outcomes coupled with robust preclinical results in our immuno-oncology program, further affirm the company's focused development path,” he told the Biotech Showcase Conference.

“With a much-improved regulatory landscape for the development of cancer therapeutics, we believe that there is great potential for our sd-rxRNA compounds to provide major advances that could change the paradigm in cancer treatments.

“Furthermore, the feedback that we have received, through relationships with leading cancer centers, potential business partners as well as institutional investors, in the context of last week's Biotech Showcase meeting, endorses our sharpened strategy.

“It is our goal to develop novel immuno-oncology treatments to benefit patients as well as our long-term shareholders and business partners.”

All change at Green Cures

There’s a change of management at Green Cures & Botanical Distribution Inc (OTCMKTS:GRCU) where Joseph Tragesser has resigned as chief executive with William Pitsicalis taking over.

"Joe did great work, and we are very thankful for his tireless efforts in advancing the company towards cannabis and CBD-based objectives," said the new CEO. "We all wish you well in your future endeavors."

The company develops, produces and distributes what it describes as premium hemp-based products.

They are used in medical, skin care, beauty, fashion and lifestyle, branded under the Original Hollywood Hemp logo.

It also develops beverages branded under the Iconic Beverages label.

Haemorrhoid cream green light

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has received a product license in Canada for its lidocaine-based pain cream Xyralid.

It is used for the treatment of haemorrhoids and the sign-off means it can be sold without a prescription.

“We are very happy that Health Canada has approved our Xyralid drug in Canada,” said chief executive, Dr Bassam Damaj.

It is the company’s sixth product on the Canadian market.

Popular on the bulletin boards:


Friendable Inc (OTCMKTS:FDBL)

Acology Inc (OTCMKTS:ACOL)

FutureLand Corp (OTCMKTS:FUTL)

View full RXII profile View Profile

RXi Pharmaceuticals Timeline

Related Articles

Vial of pills
May 17 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © personabelovo.ru, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.